10-K: Nutriband Reports FY26 Results, Focus on AVERSA Fentanyl

Nutriband Inc. filed its annual report for the fiscal year ended January 31, 2026, detailing progress on its AVERSA Fentanyl abuse-deterrent transdermal system and financial performance from its contract manufacturing segment.

Summary

• Nutriband Inc. reported revenues of $2,036,651 for the year ended January 31, 2026, a slight decrease from $2,139,537 in the prior year, primarily from its Pocono Pharmaceuticals segment.
• The company incurred a net loss of $8,229,632 for the fiscal year 2026, compared to a net loss of $10,482,617 in fiscal year 2025.
• Research and development expenses for AVERSA Fentanyl decreased to $1,891,129 in FY26 from $3,119,134 in FY25, attributed to reduced labor costs.
• Selling, general, and administrative expenses increased significantly to $6,993,140 in FY26 from $4,313,810 in FY25, largely due to increased equity-based expenses.
• The company's lead product, AVERSA Fentanyl, is progressing with a completed meeting with the FDA regarding CMC plans and is moving towards an IND filing for a Human Abuse Potential study.
• Nutriband has secured patents for its AVERSA abuse deterrent technology in 46 countries, with coverage extending to 2035, and has filed a provisional patent application to further strengthen its IP.
• The company's financial position shows cash and cash equivalents of $4,574,857 as of January 31, 2026, with working capital of $4,204,437.
• A legal proceeding is ongoing against Joseph Gunnar, LLC and Lucosky Brookman LLP, with Nutriband denying allegations and pursuing counterclaims.
• The company's common stock and warrants are listed on The Nasdaq Stock Market under symbols NTRB and NTRBW, respectively.
• Nutriband issued a Series A Convertible Preferred Stock dividend to shareholders on July 25, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the continued net loss, increased operating expenses, and a slight revenue decline, despite progress in product development and IP protection.

Positives

• Successful completion of a meeting with the FDA to obtain feedback on Chemistry, Manufacturing, and Controls (CMC) plans for AVERSA Fentanyl.
• Incorporating FDA feedback into the development program for AVERSA Fentanyl, moving towards an IND filing for a Human Abuse Potential (HAP) clinical study.
• Strengthened intellectual property portfolio with patents issued in 46 countries for AVERSA technology, providing coverage until 2035.
• Filed a new provisional patent application to enhance AVERSA technology, potentially extending patent coverage to 2046.
• Secured a commercial development and clinical supply agreement with Kindeva Drug Delivery for AVERSA Fentanyl.
• Cash and cash equivalents increased to $4,574,857 as of January 31, 2026, indicating improved liquidity.
• The company's management believes its operations are sufficient to continue as a going concern.

Negatives

• Net loss of $8,229,632 for the year ended January 31, 2026.
• Revenue decreased slightly to $2,036,651 in FY26 from $2,139,537 in FY25.
• Gross profit decreased due to lower margins on tape sales.
• Selling, general, and administrative expenses increased significantly by approximately 62% to $6,993,140 in FY26, primarily due to equity-based expenses.
• The company's 4P Therapeutics segment generated no revenue in FY26.
• The company disclosed material weaknesses in its internal controls over financial reporting.
• The company is involved in a lawsuit with Joseph Gunnar, LLC and Lucosky Brookman LLP, seeking significant damages.

Risks

• The company is subject to the risks common to start-up, pre-revenue medical delivery device enterprises, including undercapitalization and cash shortages.
• Failure to obtain necessary funding to develop proposed products could hinder progress.
• The success of clinical trials for its products is uncertain and critical for development.
• Delays in regulatory review and approval from the FDA could significantly impact commercialization.
• The company may face challenges in establishing manufacturing and distribution operations or securing agreements with qualified third parties.
• Market acceptance of its products is not guaranteed.
• Competition from existing products or new entrants could affect market share.
• Potential product liability claims and adverse events could arise.
• The company's ability to protect its intellectual property is crucial and subject to legal challenges.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The ongoing lawsuit with Joseph Gunnar, LLC and Lucosky Brookman LLP poses a financial and operational risk.

Future Outlook

The company is focused on advancing its AVERSA Fentanyl product through clinical development and FDA approval, with an expectation of increased demand in the subsequent year for its Pocono Pharmaceuticals segment. Management believes it has sufficient funds to operate for at least one year.

Management Comments

• Management believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these consolidated financial statements, which indicates improved operations and the Company's ability to continue operations as a going concern.
• Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.

Industry Context

StockSavvy.ai notes that Nutriband's focus on abuse-deterrent transdermal drug delivery, particularly for opioids like fentanyl, addresses a significant public health concern and a market need for safer alternatives. The company's strategy to leverage the 505(b)(2) NDA pathway for its AVERSA products is a common approach to expedite development for drugs with established safety profiles.

Corporate Governance

Legal Proceedings

• The Company is a defendant in a lawsuit initiated by Joseph Gunnar, LLC and Lucosky Brookman LLP, alleging breach of contract, fraudulent activities, and tortious interference, seeking over $500,000 in damages plus punitive damages and legal fees.
• Nutriband denies all allegations, claims the engagement letter was unenforceable, and has initiated counterclaims against Joseph Gunnar & Co. for intentional interference and breach of fiduciary duty, seeking $1,000,000 for each claim.

Related Party Transactions

• During FY26, a director and a related party exercised warrants, resulting in the issuance of shares.
• During FY26, employee stock options were issued to executive officers and employees, with fair value expensed.
• In FY25, the company completed an equity financing with European investors, which included related parties investing a total of $7,120,000.
• In FY25, the company received $300,000 from a credit line facility with TII Jet Services LDA, which was later converted into common stock and warrants.

Stakeholder Impact

• Shareholders may experience dilution from future equity issuances.
• The ongoing legal proceedings could negatively impact the company's financial resources and reputation.
• The company's ability to secure future funding is critical for its product development and operations.

Next Steps

• Proceed with an IND filing in support of a Human Abuse Potential (HAP) clinical study for AVERSA Fentanyl.
• Incorporate FDA feedback into the development program for AVERSA Fentanyl.
• Continue to build on proprietary positions for product candidates.
• Seek trademark protection for AVERSA in the United States and internationally.
• Consider developing products for strategic international markets.

Key Dates

Recommendation

Nutriband is in the early stages of drug development with a promising technology (AVERSA) but faces significant financial and regulatory hurdles. While the FDA meeting for AVERSA Fentanyl is a positive step, the company continues to incur substantial losses and has identified material weaknesses in internal controls. The current financial performance and ongoing litigation warrant a cautious 'hold' approach, awaiting further clinical trial data and regulatory progress.

Keywords

Nutriband, AVERSA Fentanyl, abuse deterrent, transdermal, pharmaceutical, FDA approval, clinical trials, drug delivery, Pocono Pharmaceuticals, 4P Therapeutics, Form 10-K, annual report